Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Follicular × Tirzepatide × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Obesity 6 Endometrial Neoplasms 3 Prostatic Neoplasms 2 Endometrial Hyperplasia 2 Diabetes Mellitus 2 Breast Neoplasms 2 Weight Loss 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Overweight 1 Opioid-Related Disorders 1 Lymphoma, Follicular 1 Insulin Resistance 1 Hyperplasia 1 Colorectal Neoplasms 1

Interventions

Rituximab 25 Cyclophosphamide 23 Lenalidomide 20 Prednisone 11 fludarabine 10 Vincristine 10 Doxorubicin 10 obinutuzumab 8 Bendamustine Hydrochloride 8 zanubrutinib 7 Specimen Handling 7 Magnetic Resonance Spectroscopy 7 tazemetostat 6 fludarabine phosphate 6 Biopsy 6 R-CHOP protocol 4 ibrutinib 3 Therapeutics 3 Radiotherapy 3 Exercise 3 Cyclosporine 3 venetoclax 2 tislelizumab 2 tisagenlecleucel 2 pirtobrutinib 2 copanlisib 2 axicabtagene ciloleucel 2 Whole-Body Irradiation 2 Temozolomide 2 Standard of Care 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06651177 2026-03-05

TAB

University of Cincinnati

Phase 2 Recruiting

Lymphoma, Follicular, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡